SYNchronizing Exercises, Remedies in GaIt and Cognition
NCT02808676 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 175
Last updated 2025-02-21
Summary
The proposed SYNERGIC trial is uniquely designed to evaluate the effect of aerobic and progressive resistance training exercises, combined with cognitive training and Vitamin D3 supplementation, in cognition and mobility in older adults with Mild Cognitive Impairment (MCI).
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Vitamin D3
Dose: 10000 IU, three times per week, orally.
- OTHER
-
Exercises (E)
All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
- OTHER
-
Cognitive Training (CT)
CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
- OTHER
-
placebo D3
matching placebo for Vitamin D3
- OTHER
-
control cognitive training
As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
- OTHER
-
Placebo exercise
As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
Sponsors & Collaborators
-
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
lead OTHER
Principal Investigators
-
Manuel M Montero-Odasso, MD, PhD · Gait and Brain Lab, Lawson Health Research Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-07-14
- Primary Completion
- 2020-11-24
- Completion
- 2020-11-24
Countries
- Canada
Study Locations
More Related Trials
-
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
NCT01320527 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
NCT06347315 ·Status: RECRUITING ·Phase: NA
-
Effects of a Colon-delivered Multivitamin Supplement on Brain Functioning, Immunometabolic- and Intestinal Markers in Ageing
NCT05675007 ·Status: COMPLETED ·Phase: NA
-
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
NCT00285077 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00105547 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients
NCT03514875 ·Status: WITHDRAWN ·Phase: NA
-
Anti-Oxidant Treatment of Alzheimer's Disease
NCT00117403 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)
NCT01852110 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
NCT06285240 ·Status: COMPLETED ·Phase: PHASE1
-
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
NCT03790709 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease
NCT03954613 ·Status: UNKNOWN ·Phase: PHASE4
-
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
NCT02322021 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01807026 ·Status: COMPLETED ·Phase: PHASE1
-
Lifestyle Intervention Program for Cognitive Impairment
NCT02741804 ·Status: UNKNOWN ·Phase: NA
-
Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
NCT00602680 ·Status: TERMINATED ·Phase: PHASE2
-
Healthy Adults With Mild Cognitive Impairment (MCI) and a 16-week Intervention With Mitocholine™, a Functional Food Ingredient
NCT05690724 ·Status: RECRUITING ·Phase: NA
-
Memory Impairment Study (Mild Cognitive Impairment Study)
NCT00000173 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
NCT02573740 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
NCT02820896 ·Status: COMPLETED ·Phase: PHASE1
-
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
NCT00074529 ·Status: COMPLETED ·Phase: PHASE2
-
Donepezil and Memantine in Moderate to Severe Alzheimer's Disease
NCT00866060 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
NCT04764669 ·Status: COMPLETED ·Phase: PHASE2
-
Symptomatic Treatment of Vascular Cognitive Impairment
NCT02098824 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
NCT04798989 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
NCT02079909 ·Status: COMPLETED ·Phase: PHASE2